The Potential of Therapeutic Psychedelics Drugs: An Interview with Professor Albert Garcia-Romeu
Mental health conditions like addiction and diseases like Alzheimer’s represent a great unmet clinical need. Psychedelic research at preclinical stages have shown potential for positive neurological changes in the brain for models of depression, addiction and Alzheimer's. In a recent...
3 years agoThe Potential of Therapeutic Psychedelics Drugs: An Interview with Professor Albert Garcia-Romeu
Mental health conditions like addiction and diseases like Alzheimer’s represent a great unmet clinical need. Psychedelic research at preclinical stages have shown potential for positive neurological changes in the brain for models of depression, addiction and Alzheimer's. In a recent...
3 years ago
Vaccines and Variants: How Do They Work?
As of 23 June 2021, there are 14 variants of COVID-19 which are of concern or under investigation in the UK, according to the UK government. The unique profile of COVID-19 enables rapid mutation, producing variants which are more transmissible...
3 years agoVaccines and Variants: How Do They Work?
As of 23 June 2021, there are 14 variants of COVID-19 which are of concern or under investigation in the UK, according to the UK government. The unique profile of COVID-19 enables rapid mutation, producing variants which are more transmissible...
3 years ago
Strategies Implemented for New Modalities of Therapeutic Targeting: ASOs and RNAi
In 2018, the FDA approved the first small interfering RNA (siRNA) drug, patisiran, to treat a disease known as hereditary transthyretin amyloidosis. Since then, an increasing number of oligonucleotide-based drugs have reached the market, showing advantages over small molecule drugs....
3 years agoStrategies Implemented for New Modalities of Therapeutic Targeting: ASOs and RNAi
In 2018, the FDA approved the first small interfering RNA (siRNA) drug, patisiran, to treat a disease known as hereditary transthyretin amyloidosis. Since then, an increasing number of oligonucleotide-based drugs have reached the market, showing advantages over small molecule drugs....
3 years ago
Using Translational Research to Bridge the Gap Between Preclinical and Clinical Research
The disparity between animal models and clinical efficacy is compromising the safety and efficacy of therapeutic drugs. Translational research is building the bridge between preclinical studies and therapeutic treatment. Genomic techniques and non-traditional animal models are examples of translational approaches...
3 years agoUsing Translational Research to Bridge the Gap Between Preclinical and Clinical Research
The disparity between animal models and clinical efficacy is compromising the safety and efficacy of therapeutic drugs. Translational research is building the bridge between preclinical studies and therapeutic treatment. Genomic techniques and non-traditional animal models are examples of translational approaches...
3 years ago
Moving Towards Phenotypic Screening in Drug Discovery: An Interview with Prasun Mishra
Despite the technological advances, drug discovery is still a lengthy, expensive, and difficult stage in the drug development process. Screening assays are a critical part of rapidly and thoroughly analysing vast numbers of compounds for desired biochemical activity. In a...
3 years agoMoving Towards Phenotypic Screening in Drug Discovery: An Interview with Prasun Mishra
Despite the technological advances, drug discovery is still a lengthy, expensive, and difficult stage in the drug development process. Screening assays are a critical part of rapidly and thoroughly analysing vast numbers of compounds for desired biochemical activity. In a...
3 years ago
Targeted Protein Degradation: A Potential Tool for Discovering Druggable Targets
Drug discovery is the first step in therapeutic breakthroughs. Unfortunately, this cannot occur without target discovery - the identification and validation of druggable targets. Whether it be proteins or small molecules, discovering a ‘druggable’ biological target can be a challenge...
3 years agoTargeted Protein Degradation: A Potential Tool for Discovering Druggable Targets
Drug discovery is the first step in therapeutic breakthroughs. Unfortunately, this cannot occur without target discovery - the identification and validation of druggable targets. Whether it be proteins or small molecules, discovering a ‘druggable’ biological target can be a challenge...
3 years ago
Biobanks and EHR Data in Drug Design and Development
Over the last five years, drug design and development has evolved substantially with technological innovations. Electronic health records (EHRs) have played an important role in utilising health data on a digital platform in both preclinical and clinical studies. Biobanks have...
3 years agoBiobanks and EHR Data in Drug Design and Development
Over the last five years, drug design and development has evolved substantially with technological innovations. Electronic health records (EHRs) have played an important role in utilising health data on a digital platform in both preclinical and clinical studies. Biobanks have...
3 years ago
The Great Debate: The Utilisation of True AI in All Aspects of Drug Discovery
As a part of Proventa’s Medicinal Chemistry and Biology Strategy Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Gilead’s Executive Director for...
3 years agoThe Great Debate: The Utilisation of True AI in All Aspects of Drug Discovery
As a part of Proventa’s Medicinal Chemistry and Biology Strategy Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Gilead’s Executive Director for...
3 years ago
Biomarker Discovery and Validation: Current Challenges in Oncology
Biomarkers have shown significant potential across oncology clinical studies, especially in precision medicine for immunotherapy. Therefore, it is important that biomarker discovery and validation is optimised to produce the most effective drugs for patient populations. False positives and experimental bias...
3 years agoBiomarker Discovery and Validation: Current Challenges in Oncology
Biomarkers have shown significant potential across oncology clinical studies, especially in precision medicine for immunotherapy. Therefore, it is important that biomarker discovery and validation is optimised to produce the most effective drugs for patient populations. False positives and experimental bias...
3 years ago
First Potential Alzheimer’s Drug on the Brink of FDA Approval
On 7 June 2021, Biogen will receive an answer from the FDA regarding the approval of their Alzheimer’s drug, Aducanumab. Approval for this drug will represent a significant milestone in disease management for Alzheimer’s patients, in terms of slowing the...
3 years agoFirst Potential Alzheimer’s Drug on the Brink of FDA Approval
On 7 June 2021, Biogen will receive an answer from the FDA regarding the approval of their Alzheimer’s drug, Aducanumab. Approval for this drug will represent a significant milestone in disease management for Alzheimer’s patients, in terms of slowing the...
3 years ago